




Regulatory and reimbursement issues aside, what would be your most likely initial treatment choice for a patient with newly diagnosed follicular lymphoma (FL) with the following characteristics (assume that LDH and hemoglobin are normal in all cases)? Age: 60, Stage: III, Grade: 1/2, Tumor bulk: Nonbulky, Symptoms: Asymptomatic




Regulatory and reimbursement issues aside, what would be your most likely initial treatment choice for a patient with newly diagnosed follicular lymphoma (FL) with the following characteristics (assume that LDH and hemoglobin are normal in all cases)? Age: 60, Stage: III, Grade: 1/2, Tumor bulk: Nonbulky, Symptoms: Symptomatic




Regulatory and reimbursement issues aside, what would be your most likely initial treatment choice for a patient with newly diagnosed follicular lymphoma (FL) with the following characteristics (assume that LDH and hemoglobin are normal in all cases)? Age: 80, Stage: III, Grade: 1/2, Tumor bulk: Nonbulky, Symptoms: Symptomatic




Reimbursement and regulatory issues aside, do you consider rituximab/lenalidomide to be an acceptable alternative to either R-CHOP or BR as up-front therapy that should be discussed with all patients who require treatment?




Based on current clinical trial data and your personal experience, how would you compare the global efficacy of lenalidomide/rituximab to that of BR when used as up-front therapy for FL?




Based on current clinical trial data and your personal experience, how would you compare the global tolerability/toxicity of lenalidomide/rituximab to that of BR when used as up-front therapy for FL?




How would you compare the chances that an 80-year-old man with FL will die of the FL within 10 years as opposed to other causes?




What is your usual approach to maintenance therapy for a 60-year-old patient with bulky symptomatic FL who receives first-line BR and achieves a complete response?




What is your usual approach to maintenance therapy for a 60-year-old patient with FL who receives first-line BR without maintenance, presents with bulky, symptomatic disease relapse 4 years later and achieves a complete response to re-treatment with BR?




In general, how, if at all, have you incorporated subcutaneous rituximab into your management of FL?




Regulatory and reimbursement issues aside, what is your usual second-line therapy for a 60-year-old patient with FL who achieves a complete response to BR without maintenance but then experiences bulky, symptomatic disease relapse 4 years later?




Regulatory and reimbursement issues aside, what is your usual second-line therapy for a 60-year-old patient with FL who achieves a complete response to BR followed by 2 years of rituximab maintenance but then experiences bulky, symptomatic disease relapse 4 years later?




Regulatory and reimbursement issues aside, what is your usual second-line therapy for an 80-year-old patient with FL who achieves a complete response to BR without maintenance but then experiences bulky, symptomatic disease relapse 4 years later?




In general, what would be your most likely treatment recommendation for a 60-year-old otherwise healthy patient with FL who responds to BR followed by 2 years of rituximab maintenance and then R-CHOP on relapse but subsequently develops disease progression?



In general, what would be your most likely treatment recommendation for an 80-year-old otherwise healthy patient with FL who responds to BR followed by 2 years of rituximab maintenance and then rituximab/lenalidomide on relapse but subsequently develops disease progression?



Based on current clinical trial data and your personal experience, how would you compare the global efficacy of copanlisib to that of idelalisib in FL?



Based on current clinical trial data and your personal experience, how would you compare the global tolerability/toxicity of copanlisib to that of idelalisib in FL?

